AI Verdict
ISMCF has stronger fundamentals based on our AI analysis.
ISMCF vs ISCO Fundamental Comparison
| Metric | ISMCF | ISCO |
|---|---|---|
| Revenue | $42.5M | $6.9M |
| Net Income | $57.0M | $-70,000.0 |
| Net Margin | 133.9% | -1.0% |
| ROE | 7.2% | N/A |
| ROA | 7.1% | -1.3% |
| Current Ratio | N/A | 0.80x |
| Debt/Equity | 0.00x | N/A |
| EPS | N/A | $-0.01 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ISMCF vs ISCO: Frequently Asked Questions
Is ISMCF or ISCO a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), ISMCF has stronger fundamentals. ISMCF is rated SELL (78% confidence) while ISCO is rated STRONG SELL (92% confidence). This is not investment advice.
How does ISMCF compare to ISCO fundamentally?
iShares S&P GSCI Commodity-Indexed Trust has ROE of 7.2% vs International Stem Cell CORP's N/A. Net margins are 133.9% vs -1.0% respectively.
Which stock pays higher dividends, ISMCF or ISCO?
ISMCF has a dividend yield of N/A or no dividend while ISCO has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ISMCF or ISCO for long term?
For long-term investing, consider that ISMCF has SELL rating with 78% confidence, while ISCO has STRONG SELL rating with 92% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ISMCF vs ISCO?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ISMCF vs ISCO, the AI consensus favors ISMCF based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.